A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
A phase IIIB randomized, open-label, multicenter, parallel-arm study to evaluate the short-term safety and tolerability of the abacavir/lamivudine fixed-dose combination tablet administered once-daily or the separate abacavir and lamivudine tablets administered twice-daily, as part of a three or four-drug regimen, in antiretroviral naive HIV-1 infected subjects.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have HIV-1 infection.
Had not received any prior HIV treatment for more than 14 days.
At least 1000 copies of HIV-1 RNA.
Willing to provide signed informed consent.
You may not be if
Enrolled in other investigational drug studies.
Female subjects who are pregnant or breastfeeding.
History of allergy or hypersensitivity to abacavir or lamivudine.
Certain medical conditions that would make subjects ineligible.